dry eye disease

AbbVie revives DTC ads for dry eye med Restasis with a patient front and center
AbbVie revives DTC ads for dry eye med Restasis with a patient front and center
Fierce Pharma
Allergan
Restasis
dry eye disease
DTC advertising
television ads
Flag link:
Two biotechs target dry eye disease after Novartis’ Xiidra problems
Two biotechs target dry eye disease after Novartis’ Xiidra problems
Pharmaforum
dry eye disease
Novartis
Xiidra
Sylentis
Azura Ophthalmics
Flag link:
FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01
FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01
BioSpace
Oyster Point
OC-01
dry eye disease
FDA
Flag link:
Unmet Need in Dry Eye Disease Market Leaves Room for Other Drugmakers to Step In
Unmet Need in Dry Eye Disease Market Leaves Room for Other Drugmakers to Step In
BioSpace
dry eye disease
Novartis
Allergan
Sun Pharma
Bausch
Kala Pharmaceuticals
Flag link:
A little biotech's second crack at dry eye disease comes up short. And this time there will be no extra shot at success
A little biotech's second crack at dry eye disease comes up short. And this time there will be no extra shot at success
Endpoints
Aurinia Pharmaceuticals
VOS
dry eye disease
clinical trials
Flag link:
Kala Gets the Greenlight from FDA for Dry Eye Disease Treatment
Kala Gets the Greenlight from FDA for Dry Eye Disease Treatment
BioSpace
Kala Pharmaceuticals
FDA
Eysuvis
dry eye disease
Flag link:
Ocular Therapeutix announces topline phase 1 clinical trial results of OTX-CSI
Ocular Therapeutix announces topline phase 1 clinical trial results of OTX-CSI
Pharmaceutical Business Review
Ocular Therapeutix
dry eye disease
clinical trials
OTX-CS1
Flag link:
Go or no go? Vaccine panel upstages US approval decisions
Go or no go? Vaccine panel upstages US approval decisions
EP Vantage
FDA
vaccines
COVID-19
advisory panel
Eysuvis
Brilinta
Kala Pharmaceuticals
dry eye disease
Regeneron
AstraZeneca
stroke
Flag link:
Novartis introduces inflammatory villain in its first Xiidra dry eye DTC campaign
Novartis introduces inflammatory villain in its first Xiidra dry eye DTC campaign
Fierce Pharma
Novartis
Xiidra
DTC advertising
dry eye disease
Flag link:
Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra
Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra
Endpoints
Takeda
Novartis
Xiidra
Europe
EMA
dry eye disease
Flag link:
Novartis strikes out with dry eye med Xiidra in Europe
Novartis strikes out with dry eye med Xiidra in Europe
Seeking Alpha
Novartis
dry eye disease
Europe
Xiidra
CHMP
Flag link:
Ocular Therapeutix announces first patient dosed in phase 1 clinical trial of OTX-CSI to treat dry eye disease
Ocular Therapeutix announces first patient dosed in phase 1 clinical trial of OTX-CSI to treat dry eye disease
Pharmaceutical Business Review
Ocular Therapeutix
dry eye disease
clinical trials
OTX-CSI
Flag link:
Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray
Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray
Endpoints
Oyster Point Pharma
dry eye disease
OC-01
Allergan
Restasis
Shire
Xiidra
Flag link:
With positive key trial, Kala Pharma's dry eye drug Eysuvis emulates approval path set by Xiidra
With positive key trial, Kala Pharma's dry eye drug Eysuvis emulates approval path set by Xiidra
Endpoints
Kala Pharma
Eysuvius
dry eye disease
clinical trials
Flag link:
Neuroptika announces enrollment of first patient in phase 2 clinical trial for dry eye disease
Neuroptika announces enrollment of first patient in phase 2 clinical trial for dry eye disease
Pharmaceutical Business Review
Neuroptika
dry eye disease
NRO-1
clinical trials
Flag link:
Aerie Pharmaceuticals agrees to acquire Avizorex Pharma
Aerie Pharmaceuticals agrees to acquire Avizorex Pharma
Pharmaceutical Business Review
Aerie Pharmaceuticals
Avizorex Pharma
M&A
ophthalmic
dry eye disease
Flag link:
Upcoming events – Axsome takes on migraine and Kala looks to dry eye again
Upcoming events – Axsome takes on migraine and Kala looks to dry eye again
EP Vantage
Axsome Therapeutics
migraines
AXS-07
Kala Pharmaceuticals
clinical trials
KP-121
dry eye disease
Flag link:
Sun Pharma launches CEQUA for treatment of dry eye disease in US
Sun Pharma launches CEQUA for treatment of dry eye disease in US
Pharmaceutical Business Review
Sun Pharma
dry eye disease
Cequa
drug launches
Flag link:
Oyster Point Pharma Files for $85 Million IPO
Oyster Point Pharma Files for $85 Million IPO
CP Wire
Oyster Point Pharma
dry eye disease
OC-01
IPOs
Flag link:
Oyster Point Pharma Files for $85 Million IPO
Oyster Point Pharma
dry eye disease
OC-01
IPOs
Flag link:

Pages